

EXHIBIT 423



Project Initiation Document

PROJECT INITIATION FOR 5046 Suspicious Order Monitoring

Prepared By:
Document Version:
Last Updated On:

Karyn Kunzig
1.0
October 2, 2013

Approvals:

Name: **Date:**

Chair/Sponsor: Wilson Lester

Signature: _____

Business Representative: Janet Hart

Signature: _____

Business Representative: Sophia Lai

Signature: _____

IS Representative: Karyn Kunzig

Signature: _____

Confidential

Page 1

{ DATE \@ "M/d/yyyy" }



Template Version 2.4



Project Initiation Document

Table of Contents

Approvals:.....	1
Background / Summary of the Project:	3
Project Scope:	3
Requirements:	4
Assumptions:.....	7
Risks:	7
Interrelated Projects:.....	7
Time Line:.....	8
Cost Estimate:	9
Benefit Estimate:	9
Project Team Stakeholders	11
Appendix A – Controllable Parameters.....	12
Appendix B – Reason Codes.....	15





Project Initiation Document

Background / Summary of the Project:

The purpose of this project is to develop effective controls against the diversion of controlled substances and conduct adequate due diligence to ensure that controlled substances distributed from the Distribution Centers are for legitimate patient needs. Rite Aid must ensure compliance with 21 U.S.C. 823 and/or C.F.R. 1307.74(b) to detect and report suspicious orders of controlled substances through the Distribution Centers.

Project Scope:

This project involves review of all sources of Pharmacy orders into the Distribution Centers. The Pharmacy Replenishment Order Review application will be modified to use separate override parameters for Controlled and Non-controlled Drugs. Controlled Drugs will be completely blocked from the Billing Manual Order Screens.

A portal application will be developed to identify potentially suspicious orders. DC personnel will contact the store and enter a reason code for the unusually high order quantity. Select reason codes will trigger follow up by **Loss Prevention Government Affairs** as well as a temporary block of overrides for this store.

Various reporting will be available to identify trends in order overrides, increased volume of controlled substance ordering, and repeated downward cycle counts. Both the DEA Audit Reports and Override Reason Code processing will be available on-demand for DEA inquiries.

No changes will be made to the actual Replenishment algorithms, McKesson Order process, Billing Allocations process, or WMS Systems.

Confidential



Page 3

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

Requirements:

Order Creation

Treatment Type	Radiotherapy (%)	Chemotherapy (%)	Surgery (%)	Immunotherapy (%)
1	10	10	10	70
2	10	10	10	70
3	10	10	10	70
4	10	10	10	70
5	10	10	10	70
6	10	10	10	70
7	10	10	10	70
8	10	10	10	70
9	10	10	10	70
10	10	10	10	70
11	10	10	10	70
12	10	10	10	70
13	10	10	10	70
14	10	10	10	70
15	10	10	10	70
16	10	10	10	70
17	10	10	10	70
18	10	10	10	70
19	10	10	10	70
20	10	10	10	70
21	10	10	10	70
22	10	10	10	70
23	10	10	10	70
24	10	10	10	70
25	10	10	10	70
26	10	10	10	70
27	10	10	10	70
28	10	10	10	70
29	10	10	10	70
30	10	10	10	70
31	10	10	10	70
32	10	10	10	70
33	10	10	10	70
34	10	10	10	70
35	10	10	10	70
36	10	10	10	70
37	10	10	10	70
38	10	10	10	70
39	10	10	10	70
40	10	10	10	70
41	10	10	10	70
42	10	10	10	70
43	10	10	10	70
44	10	10	10	70
45	10	10	10	70
46	10	10	10	70
47	10	10	10	70
48	10	10	10	70
49	10	10	10	70
50	10	10	10	70
51	10	10	10	70
52	10	10	10	70
53	10	10	10	70
54	10	10	10	70
55	10	10	10	70
56	10	10	10	70
57	10	10	10	70
58	10	10	10	70
59	10	10	10	70
60	10	10	10	70
61	10	10	10	70
62	10	10	10	70
63	10	10	10	70
64	10	10	10	70
65	10	10	10	70
66	10	10	10	70
67	10	10	10	70
68	10	10	10	70
69	10	10	10	70
70	10	10	10	70
71	10	10	10	70
72	10	10	10	70
73	10	10	10	70
74	10	10	10	70
75	10	10	10	70
76	10	10	10	70
77	10	10	10	70
78	10	10	10	70
79	10	10	10	70
80	10	10	10	70
81	10	10	10	70
82	10	10	10	70
83	10	10	10	70
84	10	10	10	70
85	10	10	10	70
86	10	10	10	70
87	10	10	10	70
88	10	10	10	70
89	10	10	10	70
90	10	10	10	70
91	10	10	10	70
92	10	10	10	70
93	10	10	10	70
94	10	10	10	70
95	10	10	10	70
96	10	10	10	70
97	10	10	10	70
98	10	10	10	70
99	10	10	10	70
100	10	10	10	70

Confidential



Page 4

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

Suspicious Order Review

Today blanket thresholds are manually enforced at 5,000 dosage units per individual NDC per week per store regardless of dispensing volume or trends. This is a labor intensive process with opportunity for order lines to be missed. In addition, stores which truly need this quantity must order it from McKesson. A new Billing application will be developed which will:

A horizontal bar chart illustrating the percentage of the population aged 15-24 in each state and the District of Columbia. The y-axis lists the entities, and the x-axis represents the percentage, ranging from 0% to 100% in increments of 10%. Darker bars indicate higher percentages.

Entity	Percentage (%)
Mississippi	92
Louisiana	91
Alabama	89
Arkansas	88
West Virginia	87
North Carolina	86
South Carolina	85
Tennessee	84
Missouri	83
Virginia	82
Georgia	81
Montana	80
Wyoming	79
Idaho	78
North Dakota	77
South Dakota	76
Utah	75
Arizona	74
Illinois	73
Michigan	72
Wisconsin	71
Minnesota	70
Ohio	69
Indiana	68
Pennsylvania	67
Connecticut	66
New Jersey	65
New York	64
Massachusetts	63
Rhode Island	62
Vermont	61
Delaware	60
New Hampshire	59
Washington	58
Oregon	57
California	56
Hawaii	55
District of Columbia	54
Alaska	53
Texas	52
Colorado	51
Nevada	50
Wyoming	49
Wyoming	48
Wyoming	47
Wyoming	46
Wyoming	45
Wyoming	44
Wyoming	43
Wyoming	42
Wyoming	41
Wyoming	40
Wyoming	39
Wyoming	38
Wyoming	37
Wyoming	36
Wyoming	35
Wyoming	34
Wyoming	33
Wyoming	32
Wyoming	31
Wyoming	30
Wyoming	29
Wyoming	28
Wyoming	27
Wyoming	26
Wyoming	25
Wyoming	24
Wyoming	23
Wyoming	22
Wyoming	21
Wyoming	20
Wyoming	19
Wyoming	18
Wyoming	17
Wyoming	16
Wyoming	15
Wyoming	14
Wyoming	13
Wyoming	12
Wyoming	11
Wyoming	10
Wyoming	9
Wyoming	8
Wyoming	7
Wyoming	6
Wyoming	5
Wyoming	4
Wyoming	3
Wyoming	2
Wyoming	1
Wyoming	0

Confidential



Page 5

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

Trending Reports

In addition to monitoring orders daily, the need exists to monitor ordering patterns of a store over time. A new Pharmacy Replenishment Reporting application will be developed which will:

1

A 10x10 grid of black and white squares. The grid is defined by a thick black border. Inside, the pattern is as follows: the first and last columns are entirely black. The first and last rows are entirely black, except for the central 8x8 area which is white. The central 8x8 area contains a repeating pattern of black and white squares. The pattern starts with a black square in the top-left corner of the white area, followed by a white square, then a black square, and so on. This pattern repeats across all 8x8 cells of the white area.

Confidential



Page 6

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

DEA Audit

A DEA Agent may request a store provide record of all Controlled Drugs carried in their store over a select period of time. Government Affairs contacts IS to create the report which contains total purchases, transfers, and sales by drug for that period of time. The report is sent to the PDM who must add the May 1st Audit Counts to the report as well as the ending count for the audit period. A new application will be developed which will:

- Allow the DEA Audit report to be requested on-demand.
- Require the store number, begin date, and end date of the transactions to be extracted.
- Include the May 1st Audit counts.
- Include the ending On Hand for the audit period. **If no ending on hand count need the capability to enter a count on the audit manually.**
- Provide the report on the Portal where it can be Exported to Excel for use by the PDM and store.
- Retain all data contained on this report for 2 years.

Assumptions:

- This process assumes that the DCs will pro-actively contact each store on the Suspicious Order Review screen.
- Corporate associates will not force distribute unreasonably large quantities of control drug items using the Merchandise Distribution or Pharmacy Replenishment Trend Adjustment applications.
- McKesson's systems contain sufficient controls to manage the DSD purchases.

Risks:

- Dedication of staff is critical to maintain the project schedule. Diversion of IS or Business team members will cause delays and a potential cost increase.

Interrelated Projects:

- This project is dependent upon the RX Tablet project due to IS Resource availability.






Project Initiation Document

Time Line:

This timeline assumes Analysis will begin upon completion of the RX Tablet project. It may realistically begin earlier dependent on the timeline we receive from Dell for that project.



Confidential

Page 8

{ DATE \@ "M/d/yyyy" }



Template Version 2.4



Project Initiation Document

Cost Estimate:

Item	Internal Resource	External Resource	Non-Resource
Development Team			
Replen Order Limits	\$87,320		
Trend Reports	\$102,280		
Suspicious Order Review	\$118,120		
DEA Audit	\$97,880		
QA Team	\$30,000		
Application Hardware			
Application Software			
Training			
Implementation			
Other			
Total	\$435,600	\$0	\$0

Benefit Estimate:

<Complete the below benefits template or embed benefits spreadsheet template here.

Provide the Benefits template located in xxxxxxxxx to your Business Partner. When returned, save it in a network directory. Highlight and copy the spreadsheet cells to be included in this document.

In this document, click Paste, Paste Special, select Paste Link, select Microsoft Excel Worksheet Object, and click OK.

To refresh the sheet later if changes have been made, right click anywhere on the table, click Update Link.>

Recent DEA fines for controlled substance distributors have been tied to shipping suspicious orders to registrants (pharmacies)

WAG \$80,000,000 (DC DEA license surrendered)

Cardinal Health \$34,000,000 (DC DEA license surrendered)

McKesson \$13,000,000

McDowell County West Virginia recently filed suit (since withdrawn) against 3 Rite Aid Pharmacy locations and 3 Independent Pharmacies in the county for excessive sale of

Confidential

Page 9

{ DATE \@ "M/d/yyyy" }



Template Version 2.4



Project Initiation Document

opioid medications. Included in the suit was language concerning suspicious orders to the three Rite Aid pharmacies, how identified, how resolved and end outcome.

DEA has stated numerous times controlled substance distributors must have a protocol to identify and report suspicious orders based on individual pharmacy volume not generic limits for all registrants.

Controlled substance distributors must have a suspicious order monitoring system in place which can be provided to and explained to the DEA on any routine inspection/visit.

Confidential



Page 10

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

Project Team Stakeholders

	Name	Phone	Email
Chair Sponsor:	Wilson Lester	[REDACTED]	[REDACTED]
Business Representative:	Janet Hart	[REDACTED]	[REDACTED]
Business Representative:	Sophia Lai	[REDACTED]	[REDACTED]
Business Representative:	Rick Chapman	[REDACTED]	[REDACTED]
IS Representative:	Karyn Kunzig	[REDACTED]	[REDACTED]
Project Manager:			
Business Team:	DC Reps? Steve Smith Scott Jacobson	[REDACTED]	[REDACTED]

Confidential



Page 11

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

Appendix A – Controllable Parameters





Project Initiation Document

The figure consists of a 10x4 grid of horizontal bar charts. Each row contains four bars of varying lengths, all colored black. The bars are positioned within a grid of light gray lines.

Confidential



Page 13

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

A 10x4 grid of horizontal bars, mostly black, representing data across 10 rows and 4 columns. The bars are of varying lengths and are positioned within a grid of light gray lines. The first column contains 10 bars, the second column contains 9 bars, the third column contains 8 bars, and the fourth column contains 9 bars. The bars are black and have varying lengths, representing different data values for each row and column.

Confidential



Page 14

{ DATE \@ "M/d/yyyy" }

Template Version 2.4



Project Initiation Document

Appendix B – Reason Codes

Confidential



Page 15

{ DATE \@ "M/d/yyyy" }

Template Version 2.4